Climb Bio, Inc.
CLYM
$1.74
$0.106.10%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 58.14% | 114.94% | 146.26% | 62.07% | 3.34% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 164.38% | 262.26% | 199.49% | 41.44% | -19.52% |
| Operating Income | -164.38% | -262.26% | -199.49% | -41.44% | 19.52% |
| Income Before Tax | 26.58% | 27.16% | -540.10% | -110.42% | -76.15% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 26.58% | 27.16% | -540.10% | -110.42% | -76.15% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 26.58% | 27.16% | -540.10% | -110.42% | -76.15% |
| EBIT | -164.38% | -262.26% | -199.49% | -41.44% | 19.52% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 64.60% | 67.47% | -344.98% | -62.22% | -44.56% |
| Normalized Basic EPS | -74.85% | -60.06% | -36.76% | 37.49% | 49.42% |
| EPS Diluted | 64.60% | 67.47% | -344.98% | -62.22% | -44.51% |
| Normalized Diluted EPS | -74.85% | -60.06% | -36.76% | 37.49% | 49.42% |
| Average Basic Shares Outstanding | 75.55% | 136.95% | 110.44% | 75.78% | 42.86% |
| Average Diluted Shares Outstanding | 75.55% | 136.95% | 110.44% | 75.78% | 42.86% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |